On February 25, 2026, Hepion Pharmaceuticals, Inc. entered into an intellectual property license agreement with Cirna Diagnostics for liver disease diagnostic assets, involving payments of $50,000 upfront, up to $2,350,000 in milestone payments, and sales milestones of up to $4,500,000.